Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134,995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, Cheng Y, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F. Si X, et al. Among authors: zhang l, zhang x. Thorac Cancer. 2019 Mar;10(3):551-556. doi: 10.1111/1759-7714.12977. Epub 2019 Jan 21. Thorac Cancer. 2019. PMID: 30666799 Free PMC article. Clinical Trial.
[Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel 
Administrated Every Three Weeks in Inoperable Advanced 
Non-small Cell Lung Cancer: 
A Retrospective Study from A Single Center].
Zhao J, Zhang X, Hu K, Wang H, Xu Y, Si X, Zhong W, Huang X, Zhang L, Wang M. Zhao J, et al. Among authors: zhang l, zhang x. Zhongguo Fei Ai Za Zhi. 2016 Nov 20;19(11):731-737. doi: 10.3779/j.issn.1009-3419.2016.11.03. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27866515 Free PMC article. Chinese.
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Chen Y, Zhou J, Wang D. Si X, et al. Among authors: zhang l, zhang x. Lung Cancer. 2018 Aug;122:32-37. doi: 10.1016/j.lungcan.2018.05.013. Epub 2018 May 18. Lung Cancer. 2018. PMID: 30032842 Clinical Trial.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. Among authors: zhang l. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Song P, Cui X, Bai L, Zhou X, Zhu X, Zhang J, Jin F, Zhao J, Zhou C, Zhou Y, Zhang X, Wang K, Wang Q, Yu Y, Zhang X, Bai C, Zhang L. Song P, et al. Among authors: zhang l, zhang j, zhang x. Thorac Cancer. 2019 May;10(5):1303-1309. doi: 10.1111/1759-7714.13078. Epub 2019 Apr 23. Thorac Cancer. 2019. PMID: 31016875 Free PMC article.
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L, He Z, Yang S, Tang H, Wu Y, Li S, Han B, Li K, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Sun Y, Wang Q. Wang L, et al. Among authors: zhang l. Transl Lung Cancer Res. 2019 Oct;8(5):575-583. doi: 10.21037/tlcr.2019.09.21. Transl Lung Cancer Res. 2019. PMID: 31737494 Free PMC article.
134,995 results
You have reached the last available page of results. Please see the User Guide for more information.